Baillie Gifford & Co. Has $172,000 Position in Cellectis S.A. (NASDAQ:CLLS)

Key Points

• Baillie Gifford & Co. cut its stake in Cellectis S.A. by 52.1%, selling 151,382 shares and now holds 139,047 shares valued at $172,000.
• Several institutional investors have changed their positions, with Wells Fargo & Company MN increasing its holdings by 103.4%.
• Cellectis reported a quarterly loss of ($0.18) EPS, missing analyst expectations, and had revenue of $12.03 million for the quarter.

Baillie Gifford & Co. lessened its stake in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 52.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,047 shares of the biotechnology company's stock after selling 151,382 shares during the quarter. Baillie Gifford & Co. owned about 0.25% of Cellectis worth $172,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLLS. Wells Fargo & Company MN raised its stake in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Millennium Management LLC acquired a new position in Cellectis in the fourth quarter valued at about $962,000. Finally, B Group Inc. acquired a new position in Cellectis in the fourth quarter valued at about $5,547,000. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Price Performance

NASDAQ CLLS traded down $0.04 during trading on Wednesday, hitting $2.78. 51,907 shares of the company's stock were exchanged, compared to its average volume of 234,501. The stock's 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.51. Cellectis S.A. has a fifty-two week low of $1.10 and a fifty-two week high of $3.10. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.44. The company has a market cap of $154.23 million, a PE ratio of -3.23 and a beta of 2.91.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Cellectis had a negative net margin of 114.82% and a negative return on equity of 62.55%. The firm had revenue of $12.03 million during the quarter, compared to analyst estimates of $12.71 million. Research analysts expect that Cellectis S.A. will post -0.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen downgraded Cellectis from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Barclays lowered their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.